Trials and Tribulations
Lifting the bridge in downtown Chicago
It’s time to talk turkey about CAR-T cell therapies!
No this isn’t a story about a certain biotech in Maryland, but rather a look at progress in solid tumours, an area where CAR-T cell therapies have struggled with persistence and durability while their IO antibody counterparts have largely excelled.
Can it be done?
What kind of challenges need to be tackled and how is progress being made?
To find out more, check out our commentary from ASCO below…
To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
